
fast-grow compani anim health
diagnost seek take modest us market
share gain expand intern time
diagnost tool
deliv stabl quarter
revisit lt target reiter buy lower pt
report normal quarter deliv modest top bottom line
beat vs consensu grew recur consum growth ahead
estim also announc promot catherin grassman compani
cao role cfo posit develop view remain activ
busi develop front notabl eu reiter guid also
indic plan revis long-term target given chang busi sinc
may analyst day previous indic feel compani lt
target achiev today updat affirm think reiter buy
rate lower pt
revs/ep beat street rev y/i came light
y/i beat street deliv profit ep
beat companion rev beat
y/i consum rev y/i beat
imag rev pvd ovp
togeth revenu declin respect vs
estim respect
new free term campaign announc launch new free
term campaign consum ship respons ordinari high level
competit abaxi expect see higher util life
deal tradit minimum reset rental program campaign
serv form discount similar competitor program may see
modest estim dip consum revenue growth near-term result
initi favor potenti stimul greater demand slightli lower
reiter guid reiter revenue guid y/i
core rev revenue guid y/i off-set non-cor
rev y/i core reiter guid
growth consum growth us imag rev growth
ou imag rev includ rev acquir franc busi
reiter opex y/i om
corpor account move manag indic make progress
corpor account includ petvetcar center move along
roll-out estim convert thu far
indic revisit lt target later year indic call
today plan updat lt target given chang busi sinc may
analyst day consist think provid specif
believ lower previous commun lt target rev
y/i om vs today rev om
compar think revenu target could hit
acquisit like base eu expect lower long-
term om make invest scale busi believ prudent
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model reiter rev y/i trim
flow lower gm rel estim
possibl pressur relat compani new free term campaign rais
ep expect slightli lower opex rel
prior think reiter rev y/i well
target announc analyst day last year remind
plan updat lt target given chang rel may
analyst day rais ep
potenti catalyst launch rotor chemistri ou june launch
element multiplex immunodiagnost analyz initi launch
cortisol news ou launch new tuck-in larger deal
potenti new financ event launch urine-fec uf analyz
ou expans recent tuck-in acquisit franc februari close
acquisit optom france-bas compani design develop manufactur
distribut vet imag product primari focu endoscopi optom
gener rev million euro employe acquir
busi modest sum resourc give busi
beachhead franc see variou opportun across europ
similar other much larger view still desir
partner larg establish firm suspect potenti deal
indic presenc franc see quit
opportun ou bolt tuck-in tune rev thu
think like remain acquisit pay deal cash
remain question us option financ view
recent mention see opportun acquir revenu
one sever possibl deal ou busi build australia
month expect first revenu australia come
also target new partner middl east ukrain eastern europ
select asian countri doesnt coverag
zts/abax impact recent indic see chang field
result zts-abax merger suggest earli think abax
longer donor point share year point share donor
split zts/abax team bundl rotor therapeut
also opin acquir abaxi acceler abil test treat
larg anim health player could follow suit impli mar acquir vca antech
boehring ingelheim bi rev acquir merial anoth
global anim health compani like elanco merck bayer hillhous china
market share dynam earlier year estim market share
anim health diagnost unit state abaxi
noth estim terribl differ
trail survey data suggest abaxi
none/greenfield caution data come
survey respons time tini fraction clinic us
survey data also repres averag last three year like exclud
abaxi recent share loss recent share gain link
recent anim health survey found
move forward combin urin fecal analyz togeth onto one
platform part result combin two expect launch uf
mark delay rel time announc may analyst day
compani origin commun urin fecal
view delay disappoint risk thesi top pick
investor need push growth box concern
valid compani earn call guid neg revenu
growth view risk thesi yet anoth bridg year
next year regardless think new product set nice futur growth
inflect think mark solid growth compani
execut intern expans possibl addit acquisit benefit
traction new product coupl possibl market share gain unit
buy unchang target price may
diagnost tool
element uf look provid automat imag annual urin sediment
exam manual point-of-car fecal flotat exam complet year
expect launch serv industri first dual urine-fec analyz
size combin opportun urin fecal
indic valid abil combin urin fecal onto one
analyz indic product launch near term
excit uf
hska near-term product launch includ element rc rotor-bas chemistri
analyz element multiplex immunodiagnost platform expect
launch limit releas basi roll broadli
hska element rc analyz design primarili ou custom first-tim
user chemistri analyz element rc abil run test
rotor vs abaxi tests/rotor view competit advantag
compar legaci non-multiplex immunodiagnost platform element
lower cost faster higher sensit allow multiplex
intend launch element total cortisol assay
compris revenu flow legaci immunodiagnost box
intend launch test heartworm lyme anaplasma ehrlichia
like opinion view test opportun
roughli custom long-term subscript model six-year
term agreement tend monthli minimum
annual price escal target activ subscrib
indic corpor vet hospit us vs
nascent chines market point rise interest veterinari invest
china evidenc hillhous capit group one china largest ventur fund
acquisit chines vet hospit
buy unchang target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price may
diagnost tool
buy unchang target price may
diagnost tool
